Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00482547 · ClinicalTrials.gov registry record · Phase 4
Study of a Urethral Catheter Coated With Eluting Silver Salts (SUCCESS)
A Phase 4 study, sponsored by C. R. Bard.
- Terminated
- Registry status
- Phase 4
- Development phase
- 1,188
- Enrollment target
NCT00482547: Clinical Trial Phase 4 study, sponsored by C. R. Bard.
NCT00482547 is a Phase 4 study that was terminated before completion, run by C. R. Bard. The registered enrollment target is 1,188 participants, above the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (129% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00482547, a Phase 4 study, was terminated before completion, sponsored by C. R. Bard.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 1,188 participants
- Enrollment target
Study Summary
Urinary catheters are often needed in hospital patients, but their use can increase the chance that a catheter associated urinary tract infection (called a CAUTI) may occur. This study will try to determine if patients who get a new silver coated catheter will have slower to time to development of a CAUTI compared to patients who get an uncoated catheter.
Primary Outcome
Time to occurrence of bUTI in subjects of both study groups who were catheterized with a study catheter for \>= 48 hours and who had evidence of bUTI after study catheter insertion. Subjects who did not have a bUTI are not included in the median calculation, so the median only includes data from non-censored observations.
Interventions
- DEVICE Hydrogel Silver Salts Coated Latex Urinary Catheter System
- DEVICE Bard silicone elastomer coated latex catheter system
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,188 participants |
| Start Date | 2007-06 |
| Est. Completion | 2008-08 |
| Phase | Phase 4 |
Why NCT00482547 stopped before completion
NCT00482547 is an interventional study that assigns participants to a tested intervention. Its 1,188 participants enrollment target places it among the larger protocols in the corpus, above the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (129% higher).
The record links to 0 conditions, and to 2 interventions - of which Hydrogel Silver Salts Coated Latex Urinary Catheter System is the first listed.
NCT00482547 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00482547 about?
NCT00482547 is a clinical study titled "Study of a Urethral Catheter Coated With Eluting Silver Salts (SUCCESS)". Urinary catheters are often needed in hospital patients, but their use can increase the chance that a catheter associated urinary tract infection (called a CAUTI) may occur. This study will try to determine if patients who get a new silver coated catheter will have slower to time to development of a...
What is the current status of trial NCT00482547?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 1,188 participants. The study started on 2007-06. Estimated completion is 2008-08.
What interventions are being tested in trial NCT00482547?
The interventions under investigation include: Hydrogel Silver Salts Coated Latex Urinary Catheter System (DEVICE), Bard silicone elastomer coated latex catheter system (DEVICE).
Who is sponsoring clinical trial NCT00482547?
This trial is sponsored by C. R. Bard, which has 75 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00482547's enrollment target sits among peer trials
1,188 63rd of 2000 higher than 1,938 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05580419 · 1,188 participants · NA
Impact of 4PCP on Practitioner and Patient Outcomes
- NCT06290869 · 1,188 participants · Phase 3
Tobacco Education and Lung Health Study (TEAL)
- NCT04293562 · 1,186 participants · Phase 3
A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
- NCT07286058 · 1,182 participants · Phase 3
Continuation Study of Zasocitinib in Adults With Psoriatic Arthritis
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia